Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature.
The clinical manifestation of disseminated intravascular coagulation (DIC) as paraneoplastic phenomenon is common in patients with lung cancer (especially in those with non small cell lung cancer).Surprisingly, only few data have been published on the prevalence of this phenomenon. Herein we present the case of a patient with metastatic giant-cell carcinoma of the lung complicated by DIC leading the patient to death. We also review the literature regarding the incidence, the pathogenesis and the therapy of DIC in NSCLC. As more effective therapy for lung cancer becomes available and patients live longer, DIC can be expected to be encountered more frequently. Because of this fact clinicians should be alert to the occurrence of such clotting disorders and should be familiar with their diagnosis and management.
Voulgaris
E
E
Department of Medical Oncology, Ioannina University Hospital, Niarxou Avenue, Ioannina 45500, Greece.
Pentheroudakis
G
G
Vassou
A
A
Pavlidis
N
N
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D002945:Cisplatin / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000209:etiology*; D000069347:Erlotinib Hydrochloride; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000209:etiology
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D002945:Cisplatin